MedTrace Logo

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

NCT00544219 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2019-05-15

No results posted yet for this study

Summary

RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.

Conditions

Interventions

BIOLOGICAL

rituximab

375 mg/m2 i.v. per cycle

DRUG

cyclophosphamide

750 mg/m2 i.v. per cycle

DRUG

doxorubicin hydrochloride

50 mg/m2 i.v. per cycle

DRUG

prednisone

100 mg/day p.o. per cycle

DRUG

vincristine sulfate

1.4 mg/m2 (max. 2.0 mg) i.v. per cycle

PROCEDURE

positron emission tomography

PET Scan during treatment

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Christoph Mamot, MD · Kantonsspital Aarau

  • Mario Bargetzi, MD · Kantonsspital Aarau

  • Giovanni Martinelli, MD · European Institute of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2012-09-30
Completion
2016-01-31

Countries

  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544219 on ClinicalTrials.gov